Get the Stockscreener App
8.31
2.24%
-0.19
After Hours:
8.50
0.19
+2.29%
Replimune Group Inc stock is traded at $8.31, with a volume of 2.24M.
It is down -2.24% in the last 24 hours and up +78.71% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
See More
Previous Close:
$8.50
Open:
$8.215
24h Volume:
2.24M
Relative Volume:
0.43
Market Cap:
$648.64M
Revenue:
-
Net Income/Loss:
$-209.96M
P/E Ratio:
-2.6297
EPS:
-3.16
Net Cash Flow:
$-176.27M
1W Performance:
-14.59%
1M Performance:
+78.71%
6M Performance:
+16.06%
1Y Performance:
-31.94%
1-Day Range:
$7.985
$8.6354
1-Week Range:
$7.985
$9.55
52-Week Range:
$2.68
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Compare REPL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
8.31 | 663.47M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| Oct-27-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-20-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-20-25 | Upgrade | Wedbush | Neutral → Outperform |
| Sep-19-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jul-23-25 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| Jul-23-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-23-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-22-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-22-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-22-25 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
Replimune reports positive data for melanoma treatment at SITC 2025 By Investing.com - Investing.com Nigeria
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025) - The Manila Times
Replimune Group Presents Positive Late-Breaking Data on RP1 Plus Nivolumab at SITC 2025 Conference - Quiver Quantitative
Replimune (NASDAQ: REPL) posts 24.8‑month DoR with RP1+nivolumab in PD‑1‑failed melanoma - Stock Titan
Using AI based signals to follow Replimune Group Inc.Inflation Watch & Target Return Focused Picks - newser.com
Smart tools for monitoring Replimune Group Inc.’s price action2025 Geopolitical Influence & Real-Time Chart Pattern Alerts - newser.com
Price momentum metrics for Replimune Group Inc. explained2025 Momentum Check & Low Risk High Win Rate Picks - newser.com
Replimune Group Reports Increased Losses Amid R&D Expansion - TipRanks
Positive Outlook for Replimune Group: Buy Rating Affirmed on Promising RP1 + Opdivo Therapy and Strong Financial Position - TipRanks
Replimune Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 - MarketScreener
Replimune (REPL) Gains Momentum with FDA's Acceptance of BLA Res - GuruFocus
What Wall Street predicts for Replimune Group Inc. stock priceJuly 2025 Momentum & Low Drawdown Investment Ideas - fcp.pa.gov.br
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
What risks investors should watch in Replimune Group Inc. stockJuly 2025 Institutional & Stepwise Swing Trade Plans - newser.com
Will Replimune Group Inc. stock benefit from AI adoptionEarnings Growth Report & Safe Capital Growth Plans - newser.com
Will Replimune Group Inc. stock deliver consistent dividendsTrade Volume Summary & Verified Chart Pattern Trade Signals - newser.com
Trend analysis for Replimune Group Inc. this week2025 Momentum Check & Low Drawdown Trading Strategies - newser.com
Replimune Group Inc. stock volume spike explainedProduct Launch & Comprehensive Market Scan Reports - newser.com
How Replimune Group Inc. stock compares to growth peersWeekly Volume Report & Capital Protection Trading Alerts - newser.com
What hedge fund activity signals for Replimune Group Inc. stockJuly 2025 Outlook & Stepwise Trade Signal Implementation - newser.com
How to use Fibonacci retracement on Replimune Group Inc.2025 Analyst Calls & Reliable Volume Spike Alerts - newser.com
How to build a custom watchlist for Replimune Group Inc.Product Launch & Accurate Technical Buy Alerts - newser.com
Replimune Group (REPL) to Release Earnings on Tuesday - MarketBeat
Why Replimune Group Inc. stock is a must watch in 2025July 2025 Market Mood & Accurate Intraday Trade Tips - newser.com
Is Replimune Group Inc. stock a buy before product launches2025 Macro Impact & Technical Confirmation Alerts - newser.com
What to do if you’re stuck in Replimune Group Inc.Market Performance Report & AI Powered Market Entry Strategies - newser.com
Replimune Group (NASDAQ:REPL) Stock Price Down 14.8%Should You Sell? - MarketBeat
BMO Capital Upgrades Replimune Group to Market Perform From Underperform, Adjusts Price Target to $11 From $2 - MarketScreener
BMO Capital Upgrades Replimune Group (REPL) - Nasdaq
REPL: Analyst Raises Price Target and Upgrades Rating to Market Perform | REPL Stock News - GuruFocus
What recovery options are there for Replimune Group Inc.Market Trend Review & Community Verified Watchlist Alerts - newser.com
Replimune stock rating upgraded by BMO Capital on improved FDA outlook - Investing.com Canada
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):